Neil McFarlane
Vorstandsvorsitzender bei ZEVRA THERAPEUTICS, INC.
Vermögen: 350 945 $ am 30.04.2024
Aktive Positionen von Neil McFarlane
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Direktor/Vorstandsmitglied | 06.04.2022 | - |
| Independent Dir/Board Member | 06.04.2022 | - | |
| ZEVRA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.10.2023 | - |
| Vorstandsvorsitzender | 10.10.2023 | - | |
| Präsident | 10.10.2023 | - |
Karriereverlauf von Neil McFarlane
Ehemalige bekannte Positionen von Neil McFarlane
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Adamas Pharmaceuticals, Inc. | Direktor/Vorstandsmitglied | 01.09.2019 | 01.11.2021 |
| Vorstandsvorsitzender | 01.09.2019 | 01.11.2021 | |
| ADAMAS PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 16.09.2019 | 01.01.2021 |
| TRAVERE THERAPEUTICS, INC. | Geschäftsführer | 15.08.2016 | 31.05.2019 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01.01.2011 | 01.01.2016 |
Ausbildung von Neil McFarlane
| University of Florida | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| Chief Executive Officer | 3 |
| Director/Board Member | 3 |
| Chief Operating Officer | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
| Adamas Pharmaceuticals, Inc. |
- Börse
- Insiders
- Neil McFarlane
- Erfahrung
